TBC1 domain family member 3 pseudogene 2Genealiases: []
Q-omics provides the consensus-scored TBC1D3P2 profile across patient tissues and cancer cell-line models. TBC1D3P2 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, TBC1D3P2 is differentially expressed in 7, with the highest sampling consensus in KIRP. Additionally, TBC1D3P2 RNA expression shows 6,349 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, KIRP, and STAD as cancer lineages where TBC1D3P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBC1D3P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBC1D3P2 survival associations across molecular data types. TBC1D3P2 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBC1D3P2 RNA expression–survival associations across cancer types. High TBC1D3P2 expression shows unfavorable associations in UCEC, LUSC, KICH, STAD and TGCT, but favorable associations in BLCA. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for TBC1D3P2 RNA expression.
This table summarizes TBC1D3P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TBC1D3P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBC1D3P2 shows higher tumor expression in KIRP, KIRC, BRCA, BLCA, LUAD and CHOL. The KIRP box plot shows higher TBC1D3P2 RNA expression in tumor versus normal tissue (log2 FC = +0.017, t-test p = .022).
This table shows molecular features associated with TBC1D3P2 in patient tissues and cancer cell lines. In patient samples, TBC1D3P2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, TBC1D3P2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST.
